Payment overview · 2025
General Payments
$1,426.47
48 reported records · 15 companies
Healthcare provider profile · identity verified
Sam Diasti, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TAMPA, FL · NPI 1730175944
Verified facts
What the public records show
CMS Open Payments records show Sam Diasti, MD received $1,426.47 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta, Wegovy.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $404.90 | 28.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.73 | 16.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.03 | 8.6% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $117.68 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $114.75 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.11 | 5.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.14 | 5.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.01 | 4.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.78 | 4.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.83 | 3.1% | 2 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $35.38 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.87 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.13 | 1.6% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $19.58 | 1.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.55 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,426.47 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $222.23 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $204.16 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $177.35 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $117.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $114.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.11 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $69.10 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.78 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.93 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $35.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 76 |
| Alprazolam | Alprazolam | 236 | 73 |
| Losartan Potassium | Losartan Potassium | 224 | 77 |
| Simvastatin | Simvastatin | 198 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 41 |
| Lisinopril | Lisinopril | 168 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 39 |
| Metformin Hcl | Metformin Hcl | 120 | 38 |
| Gabapentin | Gabapentin | 114 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 37 |
| Meloxicam | Meloxicam | 99 | 39 |
| Omeprazole | Omeprazole | 97 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 35 |
| Eliquis | Apixaban | 84 | 21 |
| Allopurinol | Allopurinol | 80 | 24 |
| Lorazepam | Lorazepam | 75 | 16 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Trazodone Hcl | Trazodone Hcl | 73 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 30 |
| Carvedilol | Carvedilol | 66 | 25 |
| Montelukast Sodium | Montelukast Sodium | 66 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 28 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 19 |
| Donepezil Hcl | Donepezil Hcl | 58 | 21 |
| Ozempic | Semaglutide | 58 | suppressed |
| Azithromycin | Azithromycin | 54 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 22 |
| Bupropion Xl | Bupropion Hcl | 50 | 17 |
| Furosemide | Furosemide | 49 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 17 |
| Clonazepam | Clonazepam | 47 | 11 |
| Finasteride | Finasteride | 45 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | 15 |
| Methylprednisolone | Methylprednisolone | 40 | 35 |
| Famotidine | Famotidine | 39 | 18 |
| Potassium Chloride | Potassium Chloride | 38 | 17 |
| Valsartan | Valsartan | 38 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Ezetimibe | Ezetimibe | 23 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,426.47 · 48 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EVENITY, General - Pain Management, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, Kerendia, Korlym, LUNA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error